This site is intended for US healthcare professionals only.

Prescribing InformationConnect
EXPAREL Logo
home-hero.png

The Operating Room is Yours to Control.

Their Postsurgical Pain Can Be Too.

Discover EXPARELButton Icon

Optimize Recovery With EXPAREL—A Long-Lasting Postsurgical Pain Control Treatment Option

EXPAREL is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block.
Safety and efficacy have not been established in other nerve blocks.

EXPAREL is a trusted and proven option for postsurgical pain management, used in over 15 million patients to date

Can control postsurgical pain up to 96 hours1-6

EXPAREL provides lasting pain relief through the critical days following surgery, targeting pain when at its worst.7-10

Explore EfficacyButton Icon
Demonstrated a robust safety profile3-6,11-14

EXPAREL has proven safety, supported by extensive preclinical and clinical trial data across various procedures and patient populations.

See Safety InfoButton Icon
Offers pain control tailored to your patients’ needs

EXPAREL is administered during surgery and offers versatile administration options that make it adaptable for a wide range of procedures.

View Dosing & AdministrationButton Icon

For us today, we do big surgeries as an outpatient, and the only way we could do that, and serve our patients well is to have the tools to provide pain relief that is lasting. And a good example of that is EXPAREL.

Dr Sameh Labib

Navigate Access & 
Reimbursement

Increased reimbursement measures are helping remove cost barriers, expanding access to EXPAREL.15,16

Get Access DetailsButton Icon
get-access-details-banner.png

Contact

an EXPAREL representative

Connect With a RepButton Icon
home-contact-banner-new.png
References
  1. Schwartz G, Gadsden JC, Gonzales J, et al. A phase 3 active-controlled trial of liposomal bupivacaine via sciatic nerve block in the popliteal fossa after bunionectomy. J Clin Anesth. 2024;94:111402.
  2. Gadsden J, Hamilton M, Schwartz G, et al. Liposomal bupivacaine via adductor canal block after total knee arthroplasty: a randomized, double-blind, phase 3 trial. Poster presented at: 48th Annual Regional Anesthesiology and Acute Pain Medicine Meeting; April 20, 2023; Hollywood, FL. Poster 4381.
  3. Patel MA, Gadsden JC, Nedeljkovic SS, et al. Brachial plexus block with liposomal bupivacaine for shoulder surgery improves analgesia and reduces opioid consumption: results from a multicenter, randomized, double-blind, controlled trial. Pain Med. 2020;21(2):387-400. doi:10.1093/pm/pnz103
  4. Mont MA, Beaver WB, Dysart SH, Barrington JW, Del Gaizo DJ. Local infiltration analgesia with liposomal bupivacaine improves pain scores and reduces opioid use after total knee arthroplasty: results of a randomized controlled trial. J Arthroplasty. 2018;33(1):90-96.
  5. Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. 2011;28(9):776-788. doi:10.1007/s12325-011-0052-y
  6. Gorfine SR, Onel E, Patou G, Krivokapic ZV. Bupivacaine extended release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum. 2011;54(12):1552-1559.
  7. Small C, Laycock H. Acute postoperative pain management. Br J Surg. 2020;107(2):e70-e80. doi:10.1002/bjs.11477
  8. Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. J Pain Res. 2017;10:2287-2298. doi:10.2147/JPR.S144066
  9. Joshi GP, Ogunnaike BO. Consequences of inadequate postoperative pain relief and chronic persistent postoperative pain. Anesthesiol Clin North Am. 2005;23(1):21-36. doi:10.1016/j.atc.2004.11.013
  10. Eubanks AL, Grabski DF, Pollack J, et al. A multimodal protocol utilizing liposomal bupivacaine rib blocks leads to opioid reduction in patients undergoing the Nuss procedure. J Thorac Dis. 2021;13(11):6363-6372. doi:10.21037/jtd-21-1314
  11. Minkowitz HS, Onel E, Patronella CK, Smoot JD. A two-year observational study assessing the safety of DepoFoam bupivacaine after augmentation mammaplasty. Aesthet Surg J. 2012;32(2):186-193. doi:10.1177/1090820X11434524
  12. Tirotta CF, de Armendi AJ, Horn ND, et al. A multicenter study to evaluate the pharmacokinetics and safety of liposomal bupivacaine for postsurgical analgesia in pediatric patients aged 6 to less than 17 years (PLAY). J Clin Anesth. 2021;75:11053.
  13. Viscusi ER, Sinatra R, Onel E, Ramamoorthy SL. The safety of liposome bupivacaine, a novel local analgesic formulation. Clin J Pain. 2014;30(2):102-110. doi:10.1097/AJP.0b013e318288e1f6
  14. Naseem A, Harada T, Wang D, et al. Bupivacaine extended release liposome injection does not prolong QTc interval in a thorough QT/QTc study in healthy volunteers. J Clin Pharmacol. 2012;52(9):1441-1447. doi:10.1177/0091270011419853
  15. Voices for non-opioid choices. Voices for non-opioid choices coalition applauds Congress for expanding access to non-opioid pain management options in end-of-year legislative package to combat addiction crisis. Published December 23, 2022. Accessed March 10, 2025. https://nonopioidchoices.org/wp-content/uploads/2022/12/Voices-Press-Statement-NOPAIN-Act-Passage-12.23.22.pdf
  16. Pacira BioSciences, Inc. Centers for Medicare and Medicaid Services (CMS) establishes additional payment for iovera in outpatient settings. Published November 4, 2024. Accessed March 10, 2025. https://investor.pacira.com/node/17676/pdf